Maridonneau-Parini I, Harpey C
Br J Clin Pharmacol. 1985 Aug;20(2):148-51. doi: 10.1111/j.1365-2125.1985.tb05047.x.
The effect of trimetazidine, 1-(2, 3, 4 trimethoxybenzyl)piperazine di-hydrochloride, on membrane damage induced by oxygen free radicals in red cells was studied in seven healthy volunteers after oral administration. Red cells collected prior to and after a 7 day treatment period with trimetazidine were incubated in the presence of phenazine methosulphate (an intracellular oxygen free radical generator) and diethyldithiocarbamate (a Cu-Zn superoxide dismutase inhibitor). The loss of intracellular K+ induced by oxygen free radicals and the membrane content of peroxidated lipids were significantly reduced in red cells collected after the period of treatment. These results indicate a potent antioxidant activity of trimetazidine which could explain its cardioprotective role during ischaemic and reperfusion phases in which oxygen free radicals are generated and probably implicated in the genesis of cardiac cell injury.
研究了口服1-(2,3,4-三甲氧基苄基)哌嗪二盐酸盐（曲美他嗪）对7名健康志愿者红细胞中氧自由基诱导的膜损伤的影响。在服用曲美他嗪7天治疗期前后采集的红细胞，在硫酸吩嗪（一种细胞内氧自由基生成剂）和二乙基二硫代氨基甲酸盐（一种铜锌超氧化物歧化酶抑制剂）存在的情况下进行孵育。治疗期后采集的红细胞中，氧自由基诱导的细胞内钾离子丢失和过氧化脂质的膜含量显著降低。这些结果表明曲美他嗪具有强大的抗氧化活性，这可以解释其在缺血和再灌注阶段的心脏保护作用，在这些阶段会产生氧自由基，并且可能与心脏细胞损伤的发生有关。
